| Pharmaceutical Information |
| Drug Name |
Albiglutide |
| Drug ID |
BADD_D00053 |
| Description |
Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA. |
| Indications and Usage |
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. |
| Marketing Status |
approved |
| ATC Code |
A10BJ04 |
| DrugBank ID |
DB09043
|
| KEGG ID |
D08843
|
| MeSH ID |
C534611
|
| PubChem ID |
145994868
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
Not Available |
| UNII |
5E7U48495E
|
| Synonyms |
rGLP-1 protein | Eperzan | Tanzeum | albiglutide |
|
| Chemical Information |
| Molecular Formula |
C148H224N40O45 |
| CAS Registry Number |
782500-75-8 |
| SMILES |
CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)N
C(CCCCN)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)N)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)N
C(=O)C(CCCCN)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)
C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(
=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(
CCC(=O)O)NC(=O)CNC(=O)C(CC6=CN=CN6)N |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
